Compare American Airlines Group Inc (AAL) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Airlines Group Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? American Airlines Group Inc trades at $16.43 (market cap $11.38B), while Ginkgo Bioworks Holdings Inc trades at $8.93 (market cap $610.13M). The key difference: American Airlines Group Inc is far larger — about 18.7× Ginkgo Bioworks Holdings Inc's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| AAL | DNA | |
|---|---|---|
Market Cap | $11.38B | $610.13M |
Sector | Industrials | Health |
52-Week High | $18.15 | $16.14 |
52-Week Low | $10.18 | $5.48 |
Enterprise Value | $38.97B | $647.37M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $17.20, down 4.02% amid sector rotation. The stock shows a bullish technical signal with strong moving average alignment, though RSI levels are mixed. Fundamentally, revenue grew to $54.63B in 2025, but net income fell sharply to $111M, reflecting margin pressure. Recent news highlights airline sector volatility, with fuel cost declines offering relief but broader market sentiment weighing on travel stocks.
Outlook remains cautious; analyst consensus is split with a $19.96 price target suggesting modest upside. Key risks include volatile fuel prices, competitive pressures, and high debt levels. Earnings consistency is critical for sustained recovery, with Q2 2026 results pivotal for confirming operational improvements.
DNA trades at $10.11, down 2.79% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $312.76M on $170.16M revenue in 2025, with negative cash flow and declining revenue projected into 2026. Recent news highlights include Ginkgo Bioworks' pivot to autonomous labs and insider selling activity, while analyst consensus shows a divided outlook with 45% buy ratings.
The outlook remains challenging due to persistent losses and cash burn, though technical strength offers short-term support. Investment opportunity hinges on successful execution of the autonomous lab strategy, while risks include continued negative margins, high cash consumption, and competitive pressures in biotechnology.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →
